|
|
| Vaccine id | Gene id | Name | Synonym | Stage of antigen vaccine | T cell response | B cell response | Cytokine response | Pubmed id | Pubmed link | Remarks |
| V001 | U65407 | NYVAC-pf7 | NYVAC-plasmodium falciparum7 | Multistage vaccine (sporozoiote,merozoite,circumsporozoite and sexual stage). | Yes | Yes | Not Known | 8751936 | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&list_uids=8751936 | Genes encoding seven Plasmodium falciparum antigens derived from the sporozoite (circumsporozoite protein and sporozoite surface protein 2), liver (liver stage antigen 1), blood (merozoite surface protein 1, serine repeat antigen, and apical membrane antigen 1), and sexual (25-kDa sexual-stage antigen) stages of the parasite life cycle were inserted into a single NYVAC vaccinia virus strain genome to generate NYVAC-Pf7 |
| V002 | AF063137 | TRAP or SSP-2 | Thrombospondin related adhesive protein or Sporozoite surface protein 2. | Pre-erythrocytic. | Yes | Yes | Yes | 10697897 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10697897&ordinalpos=494&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | This molecule has potential to increase the protective efficiency of available sporozoite malaria vaccines. |
| V003 | AF209925 | STARP | Sporozoite Threonine and Asparagine Rich Protein | Pre-erythrocytic. | Yes | Yes | Yes(IFN-gamma ) | 9368603 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=9368603&ordinalpos=9&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | STARP is a P. falciparum sporozoite surface protein having immunogenic properties. |
| v004 | S81602 | SALSA | Sporozoite and Liver Stage Antigen. | Pre-erythrocytic. | Yes | Yes | Not Known | 8609407 | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=pubmed&list_uids=8609407 | It is a 70-kDa protein, expressed in both sporozoite and liver stages (SALSA), with a vaccine potential that stems from its antigenic features |
| V005 | AJ298804 | LSA-3 | Liver Stage Antigen-3 | Pre-erythrocytic | Yes | Yes(low) | Yes(IFN gamma). | 11062538 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=Protection%20against%20Plasmodium%20falciparum%20malaria%20in%20chimpanzees%20by%20immunization%20with%20the%20conserved%20pre-erythrocytic%20liver-stage%20antigen%203 | This antigen is expressed both in the mosquito and liver-stage parasites. This Plasmodium falciparum 200-kilodalton protein is highly conserved, and showed promising antigenic and immunogenic properties |
| V006 | NIL | Spf66 | Synthetic P.falciparum 66 | Asexual Blood-Stage. | Yes(low) | Yes(high) | Yes(IL-4,INF gamma). | 17040762 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=17040762 | It is a synthetic malaria vaccine containing peptides derived from 3 asexual blood stage proteins of P. falciparum. |
| V007 | AF006065 | RTS,S/AS02 or SBAS2 | RTS,S/ASO2 or SBAS2 adjuvant. | Pre-erythrocytic (Circumsporozoite). | Yes(high) | Yes(high) | Yes(IFN-gamma). | 11747915 | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=11747915 | RTS,S/AS02 is a pre-erythrocytic malaria vaccine based on the circumsporozoite surface protein of Plasmodium falciparum fused to HBsAg, incorporating a new adjuvant (AS02). Among all candidate vaccines developed thus far, only the RTS,S/AS02A vaccine has consistently been demonstrated to be well tolerated and provide significant protective efficacy in challenge studies and clinical trials in malaria-endemic countries. |
| V008 | NIL | MuSTDO | Multiple Stage DNA Operation | Pre-erythrocytic(CSP based DNA vaccine). | Yes(high) | Yes(very low). | Yes | 11438836 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=MuSTDO%20vaccine | MuStDO 5 is a multivalent plasmid DNA vaccine for malaria comprised of five plasmid DNAs encoding five proteins from Plasmodium falciparum and one plasmid DNA encoding human GM-CSF. It was found to be safe and tolerable. |
| V009 | NIL | MSP-1,MSP-2 ,RESA | Combination B | Asexual Blood-Stage. | Yes(high) | Yes(low) | Not Known | 17054281 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17054281&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Combination B is a mixture of three blood-stage antigens delivered in an oil and water emulsion. . A vaccine with multiple allelic forms of the putative effective component of Combination B is being developed for further trials |
| V010 | EF563849 | MSP-1(19kDa). | Merozoite Surface Protein -1 | Asexual Blood-Stage. | yes(low) | Yes(low) | Yes(IL-4,IL-5, INF gamma) | 10519944 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10519944&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | 195-kDa protein breaks down to 19-kDa. Abs to 19-kDA reduces efficiency erythrocyte invasion. |
| v011 | AY343089 | MSP1(42)-FVO/Alhydrogel . | Merozoite Surface Protein1(42kDa) FVO allelic vaccine candidate. | Pre-erythrocytic | Yes | Yes | Yes | 17415408 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17415408&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | The C-terminal 42-kDa region of merozoite surface protein 1 (MSP1(42)) corresponding to the two allelic forms present in FVO and 3D7 P. falciparum lines were expressed in Escherichia coli, refolded, purified, and formulated on Alhydrogel (aluminum hydroxide) and prooved to have immunogenic properties. |
| V012 | AF395808 | MSP1(42)-3D7/Alhydrogel | Merozoite Surface Protein1(42kDa) 3D7 allelic vaccine candidate | Pre-erythrocytic. | Yes | Yes | Yes | 17415408 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17415408&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | same as above. |
| V013 | A00764 | GLURP | Glutamine rich Protein | Asexual Blood-Stage. | Yes | Yes | Yes | 16914240 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16914240&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | It is a long synthetic peptide vaccine whose rationale is based on the induction of antibodies with ADCI activity. |
| V014 | DQ115971 | MSP-2 | Merzoite Surface Protein-2 | Asexual Blood-Stage. | Yes | Yes | Yes | 16797008 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16797008&ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Has variable interior repeat region, but N and C ends are conserved. It has been proposed as a vaccine candidate. |
| V015 | AF440682 | MSP3-LSP | Merozoite Surface Protein 3-Long Synthetic Peptide. | Asexual Blood-Stage. | Yes | Yes | Yes(INF gamma). | 17280744 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17280744&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | MSP3-LSP is able to stimulate an enhanced cell-mediated immune response in individuals with some degree of preexisting immunity. |
| V016 | AY496866 | PfCP-2.9 | Plasmodium falciparum Circumsporozoite protein-2.9 | Asexual Blood-Stage. | Yes | Yes | Not Known | 17241708 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17241708&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Chimeric protein 2.9 (PfCP-2.9) was constructed consisting of the C-terminal regions of two leading malaria vaccine candidates, domain III of apical membrane ag-1 (AMA-1) and 19-kDa C-terminal fragment of the merozoite surface protein 1 (MSP1). |
| V017 | NIL | FP9 ME-TRAP | Multiple Epitope-Thrombospondin-Related Adhesin Protein | Asexual Blood Stage. | Yes(strong) | Yes | Yes | 16621181 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16621181&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | The regimes used two recombinant viral vectors, attenuated fowlpox strain FP9 and modified vaccinia virus Ankara (MVA). Both encoded the pre-erythrocytic malaria antigen construct ME-TRAP |
| V018 | NIL | Pvs25H | Plasmodium vivax 25H. | Sexual-stage | Yes | Yes | Yes | 15837212 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15837212&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | The Pvs25H vaccine is a recombinant protein derived from the Pvs25 surface antigen of P. vivax ookinetes. The protein was expressed in Saccharomyces cerevisiae, purified, and adsorbed onto Alhydrogel |
| V019 | NIL | MVA prime-boost DNA Multi-epitope string +TRAP | attenuated modified vaccinia strain + Thrombospondin related adhesive protein. | Pre-erythrocytic | Yes | Not known | Yes(IFN-gamma). | 15526058 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=A%20randomised,%20double-blind,%20controlled%20vaccine%20efficacy%20trial%20of%20DNA/MVA%20ME-TRAP%20against%20malaria%20infection%20in%20Gambian%20adults. | Two vaccine vectors encoding ME-TRAP, plasmid DNA and modified vaccinia virus Ankara (MVA), when used sequentially in a prime-boost immunisation regime, induce high frequencies of effector T cells and partial protection, manifest as delay in time to parasitaemia, in a clinical challenge model. |
| V020 | NIL | MVA prime-boost FowI Pox 9 Multi-epitope string +TRAP | attenuated modified vaccinia strain | Pre-erythrocytic. | Yes(strong). | Not known | Not Known | 16621181 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16621181&ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Attenuated fowlpox strain FP9 and modified vaccinia virus Ankara (MVA), Both encode the pre-erythrocytic malaria antigen construct ME-TRAP and thus together prove to be a good vaccine candidate. |
| V021 | NIL | FALVAC-1 | Falciparum Vaccine-1 | Multi-stage vaccine. | Yes | Yes | Yes. | 12243733 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12243733&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | It is a 41 kd protein containing 21 B and T cell epitopes from a variety of pre-erythrocytic,erythrocytic and sexual stages-CS, LSA-1,MSA-1, SSP-2, MSP-2, AMA-1, RAP-1,EBA-175 and Pfg27. |
| V022 | NIL | FMP1/AS02A | Falciparum Merozoite Surface Protein/AS02A Adjuvant. | Asexual Blood Stage. | Yes | Yes | Yes(INF-gamma,IL-5). | 17442466 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17442466&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | FMP2.1/AS02A is a Plasmodium falciparum vaccine candidate. It is a recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant.This is the first PfAMA-1-based vaccine shown to elicit both potent humoral and cellular immunity in humans |
| V023 | NIL | ICC-1132 | Malarivax | Pre-erythrocyte (CSP based). | Yes(high) | Yes(low) | Yes(INF-gamma). | 15603885 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15603885&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | a recombinant virus-like particle comprising of a modified hepatitis B core protein with a B cell (NANP) and two T cell epitopes of Plasmodium falciparum circumsporozoite protein (CSP), |
| V024 | AF193769 | Pfs25/Pvs25 | Plasmodium falciparum25/ Plasmodium vivax25 | Sexual-stage | Yes | Yes(high) | Not Known | 17686163 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=Pfs25/Pvs%2025%20 | It has the capability to block development of sexual stages and sporozoite development. |
| V025 | L25843 | Pfs28/Pvs28. | Plasmodium falciparum28/ Plasmodium vivax28 | Sexual-stage | Yes | Yes(high) | Not Known | 9990863 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=9990863&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | It is a 28kDa ookinite Surface Antigen which has immunogenic properties and acts as a Transmission Blocking vaccine Candidate. |
| V026 | X81648 | Pfs48/45 | Plasmodium falciparum48/45 | Sexual-stage | Yes | Yes | Not Known | 17426022 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17426022&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Pfs48/45 a member of a Plasmodium specific protein family displays conformation dependent epitopes and is an important target for malaria transmission blocking (TB) immunity. |
| V027 | L08135 | Pfs230 | Plasmodium falciparum230 | Sexual-stage | Not Known. | Yes | Not Known | 10599074 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10599074&ordinalpos=8&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Antibodies raised against an Escherichia coli-produced recombinant protein encoding a 76-kDa section (region C) of malaria transmission-blocking vaccine candidate, Pfs230, have shown to significantly reduce the ability of Plasmodium falciparum parasites to infect mosquitoes . |
| V028 | DQ995632 | VAR2CSA | Not Known | Not Known | Not Known | Yes | Not Known | 17669514 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17669514&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | VAR2CSA is the main candidate for a pregnancy malaria vaccine |
| V029 | DQ027014 | PfEMP-1 | Plasmodium falciparum Erythrocyte Membrane Protein. | Erythrocytic | Yes | Yes(low) | Yes( IFN-γ and IL-4) | 17398133 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17398133&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | This antigen is involved in sequestration of infected erythrocytes |
| V030 | NIL | FMP011+AS01B or AS02A | Falciparum Merozoite Surface Protein011 + AS01B or AS02A Adjuvant. | Pre-erythrocytic. | Yes | Yes | Yes(INF gamma) | 17101665 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17101665&ordinalpos=84&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | A recombinant LSA1 protein, FMP011, has been manufactured as a preerythrocytic vaccine to induce an immune response that would have the effect of controlling parasitemia and disease in humans |
| V031 | NIL | CS102 + Montanide ISA 720 | CSP based Circum-sporozoite102 + adjuvant MontanideISA 720 | Pre-erythrocytic (circumcporozoite based) | Yes | Yes | Yes(IFN-gamma) | 17054280 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=CS102%20vaccine | It is a circumsporozoite based vaccine candidate. |
| V032 | AY950596 | EBA-175 RII-NG | Erythrocyte Binding Antigen-175 Region II non glycosylated Antigen. | Erythrocytic | Yes | Yes | Yes | 16735084 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=%20EBA-175%20RII-NG | Immunizing with this vaccine candidate can give blocking effect to merozoite invasion. |
| V033 | AF171284 | AMA1-C1/Alhydrogel + CPG 7909 | Apical Membrane Antigen1-C1/Alhydrogel + CPG 7909 . | Asexual Blood Stage. | Yes | Yes | Yes | 16434128 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16434128&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | AMA1-C1 contains an equal mixture of recombinant proteins based on sequences from the FVO and 3D7 clones of Plasmodium falciparum. The proteins when expressed in Pichia pastoris and adsorbed on Alhydrogel proved to be a good candidate vaccine. |
| V034 | NIL | MSP1 PV200L | Merzoite Surface Protein-1 Plasmodium vivax 200L | Asexual Blood Stage. | Yes | Yes | Yes(IFN gamma). | 16291762 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16291762&ordinalpos=169&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | MSP-1 from Plasmodium vivax (PvMSP-1) contains a region of significant sequence homology with the 190L subunit vaccine derived from the P. falciparum MSP-1. This can be put forward as a vaccine candidate. |
| V035 | NIL | RTS,S + TRAP | RTS,S + Thrombospondin-Related Adhesin Protein | Pre-erythrocytic. | yes(high) | Yes(high) | Yes(IL-5, INF gamma) | 15155981 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=15155981&ordinalpos=268&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Malaria vaccine RTS,S combined with thrombospondin-related anonymous protein (TRAP) and formulated with AS02A (RTS,S+TRAP/AS02A) is safe and immunogenic in adult humans and rhesus monkeys (Macaca mulatta) It has capability to induce robust B and T cell response.. |
| V036 | NIL | P30P2MSP1(19) | P30P2 Merozoite Surface Protein | Asexual Blood Stage. | yes | yes | yes | 11722185 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=High-level%20production%20and%20purification%20of%20P30P2MSP1(19),%20an%20important%20vaccine%20antigen%20for%20malaria,%20expressed%20in%20the%20methylotropic%20yeast%20Pichia%20pastoris. | P30P2MSP1(19) is a recombinant subunit vaccine derived from merozoite surface protein 1 (MSP1) of Plasmodium falciparum, the causative agent of malaria. P30P2MSP1(19) consists of two universal T-cell epitopes fused to the most C-terminal 19-kDa portion of MSP1. |
| V037 | NIL | MAP | Multiple antigen peptides | Pre-erythrocyre(CSP based). | Yes | Yes | Yes(INF gamma)F | 10501239 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=10501239&ordinalpos=514&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Multiple antigen peptides (MAPs) containing epitopes of the major surface protein of the malaria sporozoite, the circumsporozoite (CS) protein elicit antibody-mediated protection against sporozoite challenge in experimental murine and simian hosts. |
| V038 | NIL | Pf155/RESA | Pf155/Ring infeted Erythrocyte surface Antigen. | Asexual Blood Stage. | Yes | Yes | Yes(INF-gamma, IL-4). | 9352001 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=9352001&ordinalpos=17&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Immune responses to the repeat regions of the Plasmodium falciparum antigen Pf155/RESA have been extensively studied, and antibodies to the repeats are known to interfere with parasite growth both in vitro and in vivo |
| V039 | K03509 | HRP-2 | Histidine Rich Protein-2. | Erythrocytic | Yes | yes | Yes(INF-γ). | 567375 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=567375&ordinalpos=941&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Humoral response to this antigen is used to test presence of merozoites in patient’s bloodstream. |
| V040 | AF526387 | SERA5 or P126 antigen | Serine Repeat Antigen | Asexual Blood Stage. | no | Yes | yes | 16474069 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=16474069&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Plasmodium falciparum serine repeat antigen (SERA5) is a promising asexual blood stage malaria candidate vaccine |
| V041 | NIL | CS-NANP | Circumsporozoite-N-acetylneuraminic acid phosphatase | Pre-erythrocytic. | No | Yes | Yes( IL-2 and IFN-γ). | 17054280 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17054280&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | It is a synthetic sporozoite peptide P.falciparum CS protein conjugate vaccine. |
| V042 | NIL | rPvCS-1 | recombinant Plasmodium vivax circumsporozoite (CS) protein. | Pre-erythrocytic | Yes | Yes | Yes(INF gamma) | 3319650 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=3319650&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | rPvCS-1 protein can induce memory T cells which can recognize native CS antigen and functioned as T helper cells in the production of anti-sporozoite antibodies both in vivo and in vitro. |
| V043 | NIL | rPvCs-2 and rPvCS-3. | recombinant Plasmodium vivax circumsporozoite (CS) protein. | Pre-erythrocytic | Yes | Yes | Yes(INF gamma). | 1702586 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=1702586&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Compared with an earlier recombinant P. vivax CS construct, rPvCS-1, rPvCS-2 has an additional 24 amino acids at the C-terminal, which includes the thrombospondin region of homology and a putative T cell epitope. The rPvCS-3 was generated from a chemically synthesized gene that contained an additional 54 amino acids at the amino terminus and terminates at the same carboxy-terminal amino acid as rPvCS-2. |
| V044 | NIL | CVD 908-rCSP | None | Pre-erythrocytic. | Yes | Yes | Not Known | 8133113 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=CVD%20908-rCSP | rCSP, encoding amino acids 21-398 of Plasmodium falciparum circumsporozoite protein (CSP), under control of tacP was integrated into the chromosomal delta aroC locus of attenuated delta aroC, delta aroD Salmonella typhi CVD 908 and showed immunogenic properties. |
| V045 | NIL | R16HbsAg | R16 Hepatitis B Surface Antigen. | Pre-erythrocytic. | Yes | Yes | Not Known | 1835311 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=R16HbsAg | R16HBsAg is an experimental recombinant malaria vaccine consisting of 16 repeats of a four amino acid sequence (Asn-Ala-Asn-Pro or NANP) of the circumsporozoite (CS) protein of Plasmodium falciparum expressed as a fusion protein with the recombinant hepatitis B virus surface antigen (HBsAg) produced by yeast cells. |
| V046 | NIL | Malaria RCAg-1. | None | Asexual Blood Stage. | Yes | Yes | Yes(IFN-gamma and IL-4) | 17548134 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=malaria%20RCAg-1 | A polyepitope chimeric gene that encodes 11 B-cell and T-cell proliferative epitope peptides derived from eight key antigens mostly in the blood stage of Plasmodium falciparum was made. A 35-kDa antigen encoded by this gene, named Malaria RCAg-1, was purified from an E. coli expression system and found to have immunogenic properties. |
| V047 | M11145 | CSP-1 | Circumsporozoite Protein-1 | Pre-erythrocytic(Sporozoite) | Yes | Yes | Yes(INF gamma). | 10462250 | http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=10462250 | Central area of repeat sequences. Promotes strong B-cell response that produces Abs that block sporozoites in culture. Induces CD8+ and CD4+ CTL response in mice. |
| V048 | U20985 | RAP-1/RAP-2 | Rhoptry-associated proteins | Asexual blood stage | Yes | Yes(low) | Yes (IL-2, IL-4 and IFN-gamma) | 8834763 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=8834763&ordinalpos=2&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | Located near the apical end of the merozoite, the rhoptries appear to be involved in merozoite release, attachment, and invasion of erythrocytes. Promise for their potential role in vaccination comes not only from evidence of conservation, but also from indications of their immunogenicity and protective capacity in both animal trials and in vitro studies. |
| V049 | NIL | (NANP)3-TT | tetanus toxoid-(NANP)3 | Pre-erythrocytic. | Yes(low) | Yes(low) | Yes(INF gamma). | 2094588 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=2094588&ordinalpos=6&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | (NANP)3-TT is a synthetic peptide Plasmodium falciparum circumsporozoite (CS) protein conjugated to Tetanus Toxoid conjugate protein. |
| V050 | NIL | (NANP)32 tet32 | (NANP)32 conjugate tet32 | Pre-erythrocytic. | Yes | Yes | Yes(INF gamma) | 2669101 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=2669101&ordinalpos=4&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | (NANP)32 tet32 is a synthetic peptide Plasmodium falciparum circumsporozoite (CS) protein conjugated to tet32 carrier protein molecule. |
| V051 | NIL | V12.PF3.1 | None | Pre-erythrocytic. | Yes | Yes | Yes | 12602355 | http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=12602355&ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum | CSP-specific neutralizing B cell epitopes and a 'universal' T cell epitope were combined with a particulate carrier platform, the hepatitis B core antigen (HBcAg), to produce a novel pre-erythrocytic vaccine candidate. V12.PF3.1 represents an efficient and economical P. falciparum vaccine candidate for use separately or in combination with other formulations. |
